{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:15:15Z","timestamp":1740147315926,"version":"3.37.3"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Our case of a patient with untreated lymphoplasmacytic lymphoma\/Waldenstrom\u2019s macroglobulinemia with extramedullary pleural effusion is the first documented case of pleural fluid MYD88 L265P mutation status in a community hospital setting. Our patient was intolerant to 420\u2009mg ibrutinib, but still achieved a lasting complete remission, as defined by National Comprehensive Cancer Network guidelines, with a dose reduction to 240\u2009mg of ibrutinib.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 72-year-old Caucasian (white) man diagnosed with monoclonal immunoglobin M kappa lymphoplasmacytic lymphoma\/Waldenstrom\u2019s macroglobulinemia monitored without treatment for 2 years, presented with dyspnea and a left pleural effusion. At presentation, computed tomography scans of his chest, abdomen, and pelvis showed layering left pleural effusion and para-aortic lymphadenopathy. Pleural fluid cytology demonstrated B-cell lymphoma of the lymphoplasmacytic subtype, with monoclonal kappa B-cell population on flow and a positive MYD88 L265P mutation. The pleural effusion recurred post-thoracentesis and he achieved a lasting complete remission as defined by National Comprehensive Cancer Network guideline with 240\u2009mg ibrutinib.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our discussion details a comprehensive literature review of extramedullary pulmonary involvement in Waldenstrom\u2019s macroglobulinemia. Establishing a malignant etiology for pleural effusion in Waldenstrom\u2019s macroglobulinemia can be challenging, as standard techniques may be insensitive. Allele-specific polymerase chain reaction for detecting MYD88 L265P mutations is more sensitive for confirming lymphoplasmacytic lymphoma\/Waldenstrom\u2019s macroglobulinemia in pleural fluid. Extramedullary pulmonary involvement usually presents post-diagnosis of Waldenstrom\u2019s macroglobulinemia and responds well to Waldenstrom\u2019s macroglobulinemia-directed treatment regimens. Allele-specific polymerase chain reaction is a sensitive assay for detecting MYD88 L265P mutations in pleural fluid to support the diagnosis of malignant pleural effusion in the setting of Waldenstrom\u2019s macroglobulinemia and helps guide the treatment decision to use ibrutinib. Although intolerant of ibrutinib 420\u2009mg, our patient achieved complete and sustained remission of pleural effusion with a dose of 240\u2009mg with progression free survival of over 30\u2009months.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02404-x","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T23:02:36Z","timestamp":1594594956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom\u2019s macroglobulinemia: a\u00a0case report"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-9368","authenticated-orcid":false,"given":"Martin","family":"Barnes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Kaell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"LiPera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"2404_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/ajh.23880","volume":"90","author":"R Banwait","year":"2015","unstructured":"Banwait R, Aljawai Y, Cappuccio J, et al. Extramedullary Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2015;90:100\u20134.","journal-title":"Am J Hematol"},{"key":"2404_CR2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.14386","volume":"180","author":"JN Gustine","year":"2018","unstructured":"Gustine JN, Meid K, Hunter ZR, Xu L, Treon SP, Castillo JJ. MYD88 mutations can be used to identify malignant pleural effusions in Waldenstr\u00f6m macroglobulinaemia. Br J Haematol. 2018;180:578\u201381.","journal-title":"Br J Haematol"},{"key":"2404_CR3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2015;372:1430\u201340.","journal-title":"N Engl J Med"},{"key":"2404_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.6004\/jnccn.2012.0128","volume":"10","author":"KC Anderson","year":"2012","unstructured":"Anderson KC, Alsina M, Bensinger W, for the NCCN (National Comprehensive Cancer Network), et al. Waldenstr\u00f6m\u2019s macroglobulinemia\/lymphoplasmacytic lymphoma, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012;10:1211\u20139.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2404_CR5","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","volume":"121","author":"L Xu","year":"2013","unstructured":"Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051\u20138. [published correction appears in Blood. 2013;121(26):525].","journal-title":"Blood"},{"issue":"6","key":"2404_CR6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.5858\/2000-124-0891-WMPAAP","volume":"124","author":"A Mansoor","year":"2000","unstructured":"Mansoor A, Wagner RP, DePalma L. Waldenstrom macroglobulinemia presenting as a pleural effusion. Arch Pathol Lab Med. 2000;124(6):891\u20133.","journal-title":"Arch Pathol Lab Med"},{"key":"2404_CR7","unstructured":"National Comprehensive Cancer Network. Waldenstrom Macroglobulinemia \/ Lymphoplasmacytic Lymphoma (Version 1.2017). https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/waldenstroms-patient.pdf. Accessed 21 Apr 2020."}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02404-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-020-02404-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02404-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:17:42Z","timestamp":1626135462000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02404-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2404"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02404-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"16 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}